Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study.

Aucott JN, Soloski MJ, Rebman AW, Crowder LA, Lahey LJ, Wagner CA, Robinson WH, Bechtold KT.

Clin Vaccine Immunol. 2016 Sep 6;23(9):757-66. doi: 10.1128/CVI.00071-16. Print 2016 Sep.

2.

Long-term Assessment of Post-Treatment Symptoms in Patients With Culture-Confirmed Early Lyme Disease.

Weitzner E, McKenna D, Nowakowski J, Scavarda C, Dornbush R, Bittker S, Cooper D, Nadelman RB, Visintainer P, Schwartz I, Wormser GP.

Clin Infect Dis. 2015 Dec 15;61(12):1800-6. doi: 10.1093/cid/civ735. Epub 2015 Sep 18.

3.

Development of a foundation for a case definition of post-treatment Lyme disease syndrome.

Aucott JN, Crowder LA, Kortte KB.

Int J Infect Dis. 2013 Jun;17(6):e443-9. doi: 10.1016/j.ijid.2013.01.008. Epub 2013 Feb 23.

4.

Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here?

Aucott JN, Rebman AW, Crowder LA, Kortte KB.

Qual Life Res. 2013 Feb;22(1):75-84.

5.

The Clinical, Symptom, and Quality-of-Life Characterization of a Well-Defined Group of Patients with Posttreatment Lyme Disease Syndrome.

Rebman AW, Bechtold KT, Yang T, Mihm EA, Soloski MJ, Novak CB, Aucott JN.

Front Med (Lausanne). 2017 Dec 14;4:224. doi: 10.3389/fmed.2017.00224. eCollection 2017.

6.

Posttreatment Lyme disease syndrome.

Aucott JN.

Infect Dis Clin North Am. 2015 Jun;29(2):309-23. doi: 10.1016/j.idc.2015.02.012. Review.

PMID:
25999226
7.

Health care costs, utilization and patterns of care following Lyme disease.

Adrion ER, Aucott J, Lemke KW, Weiner JP.

PLoS One. 2015 Feb 4;10(2):e0116767. doi: 10.1371/journal.pone.0116767. eCollection 2015.

8.

Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans.

Luger SW, Paparone P, Wormser GP, Nadelman RB, Grunwaldt E, Gomez G, Wisniewski M, Collins JJ.

Antimicrob Agents Chemother. 1995 Mar;39(3):661-7.

9.

Update of the Swiss guidelines on post-treatment Lyme disease syndrome.

Nemeth J, Bernasconi E, Heininger U, Abbas M, Nadal D, Strahm C, Erb S, Zimmerli S, Furrer H, Delaloye J, Kuntzer T, Altpeter E, Sturzenegger M, Weber R, For The Swiss Society For Infectious Diseases And The Swiss Society For Neurology.

Swiss Med Wkly. 2016 Dec 5;146:w14353. doi: 10.4414/smw.2016.14353. eCollection 2016. Review.

10.

Sleep quality in well-defined Lyme disease: a clinical cohort study in Maryland.

Weinstein ER, Rebman AW, Aucott JN, Johnson-Greene D, Bechtold KT.

Sleep. 2018 May 1;41(5). doi: 10.1093/sleep/zsy035.

PMID:
29452400
11.

The HUMTICK study: protocol for a prospective cohort study on post-treatment Lyme disease syndrome and the disease and cost burden of Lyme borreliosis in Belgium.

Geebelen L, Lernout T, Kabamba-Mukadi B, Saegeman V, Sprong H, Van Gucht S, Beutels P, Speybroeck N, Tersago K.

Arch Public Health. 2017 Aug 7;75:42. doi: 10.1186/s13690-017-0202-z. eCollection 2017.

12.

The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis.

Rupprecht TA, Plate A, Adam M, Wick M, Kastenbauer S, Schmidt C, Klein M, Pfister HW, Koedel U.

J Neuroinflammation. 2009 Dec 30;6:42. doi: 10.1186/1742-2094-6-42.

13.

Serum inflammatory mediators as markers of human Lyme disease activity.

Soloski MJ, Crowder LA, Lahey LJ, Wagner CA, Robinson WH, Aucott JN.

PLoS One. 2014 Apr 16;9(4):e93243. doi: 10.1371/journal.pone.0093243. eCollection 2014.

14.

Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.

Ellingsen T, Hansen I, Thorsen J, Møller BK, Tarp U, Lottenburger T, Andersen LS, Skjødt H, Pedersen JK, Lauridsen UB, Svendsen A, Lindegaard H, Jacobsen S, Østergaard M, Vestergaard A, Jurik AG, Junker P, Christensen AF, Hetland ML, Hørslev-Petersen K, Stengaard-Pedersen K.

Scand J Rheumatol. 2014;43(2):91-100. doi: 10.3109/03009742.2013.803149. Epub 2013 Aug 28.

PMID:
23980529
15.

Longitudinal Transcriptome Analysis Reveals a Sustained Differential Gene Expression Signature in Patients Treated for Acute Lyme Disease.

Bouquet J, Soloski MJ, Swei A, Cheadle C, Federman S, Billaud JN, Rebman AW, Kabre B, Halpert R, Boorgula M, Aucott JN, Chiu CY.

MBio. 2016 Feb 12;7(1):e00100-16. doi: 10.1128/mBio.00100-16.

16.

Subjective symptoms after treatment of early Lyme disease.

Cerar D, Cerar T, Ruzić-Sabljić E, Wormser GP, Strle F.

Am J Med. 2010 Jan;123(1):79-86. doi: 10.1016/j.amjmed.2009.05.011.

PMID:
20102996
17.

Lyme borreliosis in southern United Kingdom and a case for a new syndrome, chronic arthropod-borne neuropathy.

Dryden MS, Saeed K, Ogborn S, Swales P.

Epidemiol Infect. 2015 Feb;143(3):561-72. doi: 10.1017/S0950268814001071. Epub 2014 May 9.

PMID:
24814098
18.

Increased CCL19 and CCL21 levels promote fibroblast ossification in ankylosing spondylitis hip ligament tissue.

Qin Y, He LD, Sheng ZJ, Yong MM, Sheng YS, Wei Dong X, Wen Wen T, Ming ZY.

BMC Musculoskelet Disord. 2014 Sep 26;15:316. doi: 10.1186/1471-2474-15-316.

19.

Enhanced levels of CCL19 in patients with advanced acquired immune deficiency syndrome (AIDS).

Damås JK, Øktedalen O, Ueland T, Landrø L, Barstad J, Müller F, Frøland SS, Flo TH, Aukrust P.

Clin Exp Immunol. 2012 Mar;167(3):492-8. doi: 10.1111/j.1365-2249.2011.04524.x.

20.

CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.

Sellam J, Rouanet S, Hendel-Chavez H, Miceli-Richard C, Combe B, Sibilia J, Le Loët X, Tebib J, Jourdan R, Dougados M, Taoufik Y, Mariette X.

Arthritis Rheum. 2013 Sep;65(9):2253-61. doi: 10.1002/art.38023.

Supplemental Content

Support Center